CCI
TRIL

Columbus Circle Investors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Columbus Circle Investors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$6.38M Buy
+433,574
New +$6.25M 0.28% 104

Other funds holding TRIL

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Columbus Circle Investors's TRIL Position: Q4 2020 in Review

Columbus Circle Investors opened a new position in Trillium Therapeutics Inc. (TRIL) in Q4 2020: 433,574 shares worth $6.38M. The stake represents 0.28% of the portfolio and ranks #104 among its holdings.

131 funds tracked by Wall St. Rank hold TRIL as of Q4 2020.

  • Columbus Circle Investors held 433,574 shares of Trillium Therapeutics Inc. worth $6.38M as of Q4 2020.
  • Trillium Therapeutics Inc. was a new Columbus Circle Investors position in Q4 2020.
  • Trillium Therapeutics Inc. made up 0.28% of Columbus Circle Investors's portfolio in Q4 2020, its #104 holding.
  • 131 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2020.

Based on Columbus Circle Investors's 13F filing for Q4 2020, filed 20 Jan 2021.